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Alport syndrome and diffuse leiomyomatosis: Deletions in the 5' end of
the COL4A5 collagen gene. Alport syndrome (AS) is an hereditary
glomerulonephritis that is mainly inherited as a dominant X-Iinked trait.
Structural abnormalities in the type IV collagen a5 chain gene
(COL4A5), which maps to Xq22, have recently been detected in several
patients with AS. The association of AS with diffuse esophageal
leiomyomatosis (DL) has been reported in 24 patients, most of them
also suffering from congenital cataract. The mode of transmission and
the location of the gene(s) involved in this association have not been
elucidated. Southern blotting using cDNA probes spanning the whole
COL4A5 and a 5' end COL4A5 genomic probe showed that three out of
three patients with the DL-AS association had a deletion in the 5' part
of the COL4A5 gene extending beyond its 5' end. This indicates that the
same gene, COL4A5, is involved in classical AS and in DL-AS and that
the transmission of DL-AS is X-linked dominant. These results also
suggest that leiomyomatosis might be due to the alteration of a second
gene involved in smooth muscle cell proliferation, which is located
upstream of the COL4A5 gene, and that there might be a contiguous
gene deletion syndrome, involving at least the genes coding for congen-
ital cataract, DL and AS.
Alport syndrome (AS) is an inherited disorder [1, 2] charac-
terized by progressive hematuric nephritis with ultrastructural
changes in the glomerular basement membrane (GBM) and
sensorineural deafness, often associated with ocular abnormal-
ities such as lenticonus and retinal anomalies [3]. AS generally
appears to be inherited as a dominant X-linked trait [2, 4] and
the AS locus has been mapped to the region Xq22-24 by linkage
analysis [5—8]. The gene COL4A5 coding for the basement
membrane-specific type IV collagen a5 chain has also been
mapped to Xq22 [9] and COL4AS structural abnormalities have
recently been found in AS patients. Thus far, 17 different
mutations have been reported by different groups in patients
from 17 different families [10—20] and 13 other COL4A5 anom-
alies have been detected in our laboratory [21—23].
Diffuse esophageal leiomyomatosis (DL) is a rare condition
characterized by benign smooth muscle cell proliferation [24].
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Sporadic and hereditary cases have been described [25—27].
Other organs, especially the female genital tract and the trache-
obronchial tree, may also be involved. The association of DL
with AS was first stressed by Garcia Torres and Guarner [28].
Twenty-eight cases from 14 families have now been docu-
mented, and cosegregation of AS and DL has been observed in
all of them [28—38]. Therefore, the association of AS and DL
cannot be considered as pure coincidence. All patients with the
DL-AS association have the renal and auditory involvement
characteristic of AS. However, a unique feature is the high
incidence of severe, congenital and bilateral cataracts, a type of
ocular involvement usually not observed in typical AS. Al-
though the mode of transmission of the DL-AS association is
dominant and frequently considered to be autosomal [28—30,
36], careful analysis of reported pedigrees fails to disclose any
male to male transmission, making dominant X-linked inheri-
tance more likely.
This association between DL and AS raises the question of
the possible pleiotropic effect of a single AS gene (COL4A5 or
another one), or of the involvement of two closely linked genes.
We have addressed this question by analyzing the COL4A5
gene in three children with DL-AS. These three children belong
to a series of 72 patients affected with AS and studied for
mutations in COL4A5, no leiomyomatosis having been detected
in the 69 others [22, Antignac et al, manuscript in preparation].
Methods
Patients
Clinical data on patients I and 2 have previously been
reported [29, 30].
Patient I, a boy, was found to have microscopic hematuria at
14 months, and bilateral cataracts were found one year later. At
the age of 4, laboratory investigation showed persistent micro-
scopic hematuria, proteinuria (0.25 g/liter), normal renal func-
tion and abnormalities of the GBM, characterized by alternating
thick and thin GBM segments. Audiometry revealed a moderate
right high-tone sensorineural hearing loss. At age 9, the boy
complained of dyspnea, retrosternal pain and post-prandial
vomiting. A barium study demonstrated marked esophageal
dilation, with abrupt luminal narrowing and displacement of the
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Fig. 1. Schematic diagram of the COL4A5
deletions in DL-AS patients. A. Schematic
representation of the aS chain of type IV
collagen. NC! refers to the noncollagenous
domain of the protein. B. Alignment of the
cDNA probes used for Southern blot analysis.
C. Schematic representation of the extent of
pti the deletions in COL4A5 cDNA in DL-ASpatients. Symbols are: open boxes, deletedpt regions; filled boxes, non-deleted regions;
—pt3 hatched boxes, 3' end breakpoint region.
distal esophagus to the right. Surgical exploration showed
thickening of the esophageal wall, mainly due to a thickening of
the inner circular muscular coat, and revealed two intramural
leiomyomas of the stomach. Partial esophagogastrectomy was
performed, and the patient recovered completely. At the latest
examination, at 17 years of age, the boy had persistent micro-
scopic hematuria, proteinuria (3.1 g124 hr), a slighly decreased
creatinine clearance (60 ml/min/l.73 m2) and bilateral neural
deafness. The child's mother presented with genital leiomyo-
mas and underwent an esogastrectomy at the age of 34 years for
DL revealed by long-standing dysphagia. She had normal
hearing and no cataract, but had persistent isolated microscopic
hematuria. No other family member had a history of deafness,
hematuria, esophageal or genital abnormalities.
Patient 2, a boy born with cleft palate and anal imperforation,
presented with macroscopic hematuria at 2 years of age, and
typical Alport syndrome GBM lesions were found by electron
microscopy. His audiogram was normal. He underwent surgery
for bilateral congenital cataracts (posterior subcapsular type) at
4 years of age. He also suffered from recurrent pulmonary
infections and swallowing difficulties. Barium studies and com-
puted tomography of the esophagus showed marked and diffuse
esophageal wall thickening with bronchial compression. The
child underwent subtotal esophagectomy and proximal gastrec-
tomy with reconstitution by colon interposition. Diffuse thick-
ening of the esophageal (15 mm) and stomach (24 mm) walls,
due to the proliferation of the smooth muscle cells of the
muscularis mucosae and the inner circular muscular coat,
extended to the upper part of the resected esophagus and to the
lower part of the resected stomach. At 7 years of age, the
patient had persistent hematuria, mild proteinuria (0.10 g/day),
normal renal function and normal audition. The child's mother
had microscopic hematuria and diffuse esophageal leiomyoma-
tosis. There was no other evidence of familial renal or muscular
involvement.
Patient 3 is a boy with microscopic hematuria, discovered
when he was 3 years old. At age 6, he underwent renal biopsy,
which disclosed thickening and splitting of the GBM. He
developed end-stage renal failure at the age of 16 and underwent
kidney transplantation. At that time he had normal hearing, a
right anterior lenticonus and mild bilateral capsular opacities.
Routine chest radiography revealed a right posterior paracar-
diac opacity. Subsequent barium esophagograms disclosed
marked esophageal dilation without peristaltic movements, and
narrowing of the esophageal junction. Endoscopy revealed
normal esophageal mucosa. As the child was asymptomatic, no
further investigations were performed. At the latest follow-up,
at age 24, the patient complained only of slight swallowing
difficulties; he had normal renal function and clinical hearing (an
audiogram could not be performed). Although no family mem-
ber could be examined, there was no family history of digestive
or renal involvement.
Methods
DNA was extracted from peripheral blood leukocytes by
standard procedure. DNA samples were digested with the
restriction endonucleases TaqI, MspI, PstI and EcoRl, under
conditions recommended by the manufacturer (Amersham).
DNA fragments were size-separated by horizontal electropho-
resis through 0.8% agarose gels and transferred by alkaline
procedure to positively-charged nylon membranes (Hybond
N, Amersham). The filters were hybridized with a set of seven
contiguous or overlapping cDNA probes spanning the entire
COL4A5 gene (Fig. 1), and with an EcoRI genomic fragment
(LA226-El) containing the first exon and 0.7kb of upstream and
0.4kb of downstream genomic sequences (Zhou et al., unpub-
lished observations). The cDNA clones included, from the 5' to
the 3' end: JZ4, HTI4-l, HTI4-2 and HT14-3, which contain the
coding sequence for the 5' untranslated region and amino acid
residues 1 to 911 (Zhou et al, unpublished observations) and a
pooi of inserts of the 3' end clones (PL3I-MD6-PC4b) coding
for residues 912 to 1685 and the 3' untranslated region [9]. The
inserts were radiolabelled by random oligomer priming. The
filters were pre- and hybridized at 65°C in a buffer consisting of
10% dextran sulfate, I M NaCI, 10% SDS and 100 g/ml
sonicated denatured salmon sperm DNA. When hybridization
was performed with the genomic probe, LA226-El, sonicated
single-stranded human DNA (150 .tg per ml) was added to the
hybridization solutions.
A 2.7 kb genomic EcoRI fragment hybridizing to the genomic
LA226-El probe containing exon I was characterized by
screening a chromosome X-enriched A phage library (ATCC
57750) by standard procedures, using the 5' end EcoRI fragment
(JZ4E) of the JZ4 cDNA as probe (Fig. I). A 15 kb clone
containing an internal 2.7 kb EcoRl fragment was isolated and
subcloned into pUCI8 for sequencing. The nucleotide sequenc-
ing was carried out using the dideoxy termination method using
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Fig. 2. Southern blots of EcoRI- and PstI-
digested DNAs from DL-AS patients probed
with JZ4. A. EcoRI-cleaved DNAs from a
female control (C) and patients 1, 3 and 2. B.
PstI-cleaved DNAs from a female control (C)
and from patients 1, 3 and 2.
universal and sequence specific primers. The reaction products
were analyzed on an automated DNA sequencer (A.L.F.,
Pharmacia).
Results
Since the complete exon size pattern of COL4AS has been
determined (Zhou et al, manuscript in preparation), exons could
have been numbered in the correct manner, from the 5' end of
the gene.
Hybridization with COL4A5 cDNA probes
Southern hybridization analyses revealed abnormalities in
the COL4A5 gene of all three patients, when studied with the
JZ4 cDNA probe, which encodes exons 1-9. The exons 1-3 and
59 are located in genomic EcoRI fragments of 1.4 kb, 3.6 kb,
5.5 kb and 10 kb (Zhou and Tryggvason, unpublished observa-
tions). Another 1.4 kb fragment and a 2.3 kb fragment contain-
ing exon 4 are not visible with JZ4, since exon 4 is a small exon
and contains an internal EcoRl site.
EcoRI-digested DNAs from patients 1 and 3 hybridized to the
JZ4 probe lacked the 1.4 kb band containing exon 1, whereas
the 3.6, 5.5 and 10 kb bands which contain exons 2, 3 and 5-9
were present (Fig. 2A). An unidentified 2.7 kb band was found
in both the patients and the control. Psi! digested DNAs also
exhibited an abnormal pattern: they lacked the 2 kb band
comprising exon 1, while the 1.7, 10 and 14kb bands containing
exons 2-9 (Zhou and Tryggvason, unpublished observations)
were present (Fig. 2B). An unidentified 4.2 kb band was also
found in both the patients and the control. Conversely, when
the DNA samples from patients I and 3 were hybridized with
the HT14-1, HT14-2, HTI4-3 probes and the pool of cDNAs
inserts (PL31-MD6-PC4b) for the 3' end of the gene, the
hybridization pattern was the same as in controls, regardless of
what restriction enzymes were used (data not shown). The
hybridization pattern of patient 2 was different (Figs, 2 and 3).
Hybridization of EcoRI-digest DNA to JZ4 revealed only the
unidentified 2.7 kb fragment, and no signal was detected with
HTI4-l. EcoRI digested DNA hybridized to HT14-2 lacked the
2.9 and 2.2 kb fragments present in controls (Fig. 3). Hybrid-
ization with HT14-3 and the 3' end cDNAs gave a normal
pattern.
These results show that the three patients have deletions of
the 5' end of the COL4A5 gene. The putative extent of these
deletions is summarized in Figure IC.
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changed to ATA. The origin, location and significance of this
fragment is unclear, but it cannot be an actual part of the
COL4A5 gene. We do not yet know if it is a pseudogene, since
it is the only genomic fragment known to hybridize to the cDNA
clones that do not belong to the COL4A5 gene (Zhou et al,
unpublished observation).
Discussion
Fig. 3. Southern blot of EcoRl-cleaved DNAsfro,n patient 2 (lanes 2,
4, 6, 8 and JO) and from a norma/female control (lanes 1, 3, 5, 7 and 9)
probed with COL4AS cDNA probes.
Hybridization with a genomic clone containing exon I
In order to examine if the 5' end of the deletions extended
upstream of exon 1, the DNAs were hybridized to the 1.4 kb
genomic EcoRI fragment, LA226-El, containing 0.7 kb of the
sequence upstream of exon I (Fig. 4). This fragment hybridized
to the corresponding 1.4 kb EcoRI and 2 kb Psi! fragments in
the control DNA, and also to the unidentified 2.7kb EcoRI and
4.2 kb PstI fragments. Only the 2.7 kb EcoRI and 4.2 kb Pstl
fragments were observed in the patients. These results con-
firmed those obtained with the eDNA probes, showing that the
DNAs of all three patients lacked exon 1 plus 0.7 kb upstream
and 0.4 kb downstream, However, both controls and patients
contained the 2.7 kb EcoRI and 4.2 kb Psi'! fragments hybrid-
izing with a sequence from exon 1.
Identification of a 2.7 kb genomic EcoRl fragment
All three patients clearly lacked exon 1, based on the hybrid-
ization pattern with the cDNA and the genomic probes. How-
ever, since they contained an unidentified 2.7 kb EcoRI frag-
ment hybridizing to a sequence from exon 1, we set out to
identify this fragment. A genomic A phage clone, LA223,
containing a 2.7 kb EcoRI fragment hybridizing to JZ4, was
isolated and the 2.7 kb fragment was subcloned and sequenced.
This insert was found to contain an 81 bp long sequence that
was 86% identical to the translated sequence of exon 1 (data not
shown). However, this sequence differed from the actual se-
quence of exon I in the COL4A5 gene, in that the initiation
codon, ATG, for methionine in the normal COL4A5 gene was
In this paper, we report deletions in the 5' part of the
COL4A5 gene and extending beyond its 5' end, in three out of
three male patients with the DL-AS association. They belong to
a series of 72 patients with AS studied for mutations in the
COL4A5 gene. The esophageal involvement varied from severe
swallowing difficulties and recurrent pulmonary infections re-
quiring large surgical resections in two patients, to a fortuitous
discovery of radiological changes in the nearly asymptomatic
third patient. Two affected mothers also had leiomyomatosis.
Two of the severely affected boys had congenital bilateral
cataracts which are not a typical feature of AS, while the mildly
affected child had unilateral lenticonus with late-onset cata-
racts.
The deletions in the 5' end of the COL4A5 gene include at
least exon 1 and extend beyond its 5' end in all three patients.
The boundaries of these deletions could not be precisely
determined, but the deletions extended at least 700 bp upstream
of exon I as shown by hybridization with the LA226-E1
genomic probe. The 3' breakpoint lies within intron I in patients
1 and 3, and is located more downstream in the region covered
by the HTI4-2 probe in patient 2. Seventeen mutations have
now been reported, by other groups, in AS patients without DL
[10—20]. Nine of them are point mutations [10, 11, 13, 17—20].
The others are deletions and/or complex rearrangements in
COL4A5 located, in most cases, in the 3' end of the gene
corresponding to the non-collagenous domain of the a5(IV)
chain [10, 12, 14, 15, 18]. One deletion in the 5' end of COL4AS,
reported in a 12-year-old male patient, has been correlated with
isolated AS [16], and a complete COL4AS deletion has been
reported in a patient with de novo isolated juvenile AS who
developed anti-GBM glomerulonephritis after transplantation
[15].
However, we report here the first description of deletions in
the COL4A5 gene in patients with the association of AS and
DL.
These findings demonstrate that the same gene (COL4A5) is
involved in classical AS and in DL-AS. The clinical involve-
ment in females, in this study as well as in the literature, shows
that DL-AS is inherited in a dominant X-linked manner. How-
ever, more patients with DL-AS must be analyzed to determine
whether all cases of DL-AS are due to mutations in the same
region of the X chromosome.
The association of deletions in the 5' end and upstream region
of the COL4A5 gene with DL-AS is intriguing since it suggests
that DL-AS could be the result of a two-gene defect, one
causing AS and another, in a closely located unidentified gene,
causing DL. This gene should lie at least 700 bp upstream the
COL4A5 gene, since no signs of open reading frame for a type
IV collagen chain sequence or for another gene sequence have
been found in this 700 bp genomic sequence (J. Zhou and K.
Tryggvason, unpublished data). Antoher possibility would be
that the defect causing both DL and AS is due to an alteration
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Fig. 4. Southern blots of EcoRI- and PstI-
digested DNAs from DL-AS patients probed
with the LA226-El genomic probe. A. EcoRI-
cleaved DNAs from a female control (C) and
patients 1, 3 and 2. B. PstI-cleaved DNAs
from a female control (C) and from patients 1,
3 and 2.
within a gene located in the first intron of COL4A5 or to a
pleiotropic effect of a mutation in the first exon. However, we
have found COL4A5 deletions including at least exon I and
extending at least 700bp beyond the 5' endof the COL4A5 gene
in three patients with AS but without Ieiomyomatosis (Antignac
et al, manuscript in preparation). In addition, two patients with
AS without DL have been reported in the literature with
deletions of the 5' end of COL4A5 [15, 16]. Although the
present findings could be due to variations in the expression of
the COL4A5 gene defect, they strongly suggest that leiomyo-
matosis is produced by a defect in a gene(s) (DL gene) located
in the vicinity upstream of the COL4A5 gene and behaving as a
tumor or growth suppressor gene [39]. Patients with DL-AS
would have large deletions encompassing the DL gene, whereas
patients with AS without DL would have shorter deletions not
reaching the DL gene. Similarly, patients with DL without AS
[24] would have mutations in the X-Iinked DL gene alone.
However, there might be other genes responsible for leiomyo-
matosis, as shown by the occurrence of familial leiomyomatosis
with autosomal dominant inheritance [26, 27].
The high percentage of congenital cataracts observed in
patients with DL-AS is most interesting. Since cataracts are not
usually observed in classical AS, they are unlikely to be the
result of mutations in the COL4A5 gene. This defect could be
due to a pleiotropic effect of the DL gene, or more probably to
a defect in a third contiguous gene, possibly that responsible for
the X-linked form of congenital cataract, the CCT gene which
has not yet been precisely mapped to the X chromosome [40].
This leads to the hypothesis of a contiguous gene syndrome,
which would include, at least, CCT, DL and COL4A5. Further
analyses, including pulse field gel electrophoresis, are required
to explore this hypothesis.
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